These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 22172822

  • 21. Steroid withdrawal five days after renal transplantation allows for the prevention of wound-healing complications associated with sirolimus therapy.
    Sandrini S, Setti G, Bossini N, Maffei C, Iovinella L, Tognazzi N, Maffeis R, Nodari F, Portolani N, Cancarini G.
    Clin Transplant; 2009; 23(1):16-22. PubMed ID: 18727661
    [Abstract] [Full Text] [Related]

  • 22. Can we eliminate both calcineurin inhibitors and steroids?
    Lebranchu Y.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446
    [Abstract] [Full Text] [Related]

  • 23. Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens.
    Gyurus E, Kaposztas Z, Kahan BD.
    Transplant Proc; 2011 Jun; 43(5):1583-92. PubMed ID: 21693238
    [Abstract] [Full Text] [Related]

  • 24. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E, Ratto E, Bellino D, Marsano L, Cassottana P, Cannella G.
    J Nephrol; 2012 Jun; 25(5):709-18. PubMed ID: 22038336
    [Abstract] [Full Text] [Related]

  • 25. Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants.
    Petero VG, Kaposztas Z, Kahan BD.
    Clin Transplant; 2010 Jun; 24(2):243-51. PubMed ID: 19694771
    [Abstract] [Full Text] [Related]

  • 26. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J.
    Transplantation; 2001 Sep 15; 72(5):777-86. PubMed ID: 11571437
    [Abstract] [Full Text] [Related]

  • 27. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
    Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, Grinyó JM, Friend P, Lawen J, Hartmann A, Schena FP, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2005 Nov 15; 80(9):1204-11. PubMed ID: 16314787
    [Abstract] [Full Text] [Related]

  • 28. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Al-Waheeb S, Hasaneen H, Awadain WH, Nawas KM, El-Sayed A, Said T, Nair MP, Nampoory MR.
    Transplant Proc; 2009 Sep 15; 41(7):2784-8. PubMed ID: 19765435
    [Abstract] [Full Text] [Related]

  • 29. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, Sirolimus Renal Function Study Group.
    Transplantation; 2002 Dec 15; 74(11):1560-7. PubMed ID: 12490789
    [Abstract] [Full Text] [Related]

  • 30. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation.
    Pescovitz MD, Nezakatgoo N, Lorber MI, Nashan B, Tedesco-Silva H, Kasiske BL, de la Cruz FJ, Russ G, Campistol J, Keown PA, International Sirolimus Study Group.
    Transplantation; 2009 Oct 27; 88(8):1010-8. PubMed ID: 19855247
    [Abstract] [Full Text] [Related]

  • 31. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M.
    J Nephrol; 2011 Oct 27; 24(5):613-8. PubMed ID: 21240873
    [Abstract] [Full Text] [Related]

  • 32. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N, Rodger RS, McMillan MA, Junor BJ.
    Transplantation; 2007 Mar 15; 83(5):582-7. PubMed ID: 17353778
    [Abstract] [Full Text] [Related]

  • 33. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 34. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
    Isr Med Assoc J; 2002 Nov 15; 4(11 Suppl):935-9. PubMed ID: 12455184
    [Abstract] [Full Text] [Related]

  • 35. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J.
    Transplantation; 1999 Nov 27; 68(10):1526-32. PubMed ID: 10589950
    [Abstract] [Full Text] [Related]

  • 36. Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen.
    Kahan BD, Podbielski J, Schoenberg L.
    Transplant Proc; 2006 Nov 27; 38(9):2842-6. PubMed ID: 17112844
    [Abstract] [Full Text] [Related]

  • 37. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH, Chadban SJ, Campbell S, Dent H, Russ GR, McDonald SP.
    Nephrology (Carlton); 2010 Apr 27; 15(3):368-76. PubMed ID: 20470309
    [Abstract] [Full Text] [Related]

  • 38. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF.
    J Am Soc Nephrol; 2006 Feb 27; 17(2):581-9. PubMed ID: 16434506
    [Abstract] [Full Text] [Related]

  • 39. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.